Baird Maintains Bullish Stance On Human Genome Sciences (HGSI) Following CHMP Positive Opinion for Benlysta

Baird reiterated their Outperform rating and $32 price target on Human Genome Sciences (NASDAQ: HGSI) following CHMP's positive opinion for Benlysta.

The firm states, "Remain buyers after CHMP's positive Benlysta opinion recommending approval in Europe. With a label and launch plan broadly within the range of expectations, we are not changing our EU revenue estimates. That said, given some recent concerns around an EU delay, we anticipate the stock should be up on this news. With reasonable near-term commercial expectations, we continue to recommend purchase into the low-$30s."


For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $27.98 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald